{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Mitoxantrone+hydrochloride", "query": { "intervention": "Mitoxantrone hydrochloride" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 176, "total_pages": 18, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Mitoxantrone+hydrochloride&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-24T06:04:59.218Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00331344", "title": "Treating Patients With Metastatic Prostate Cancer Not Responding to Hormone and Chemotherapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Adenocarcinoma of the Prostate", "Recurrent Prostate Cancer", "Stage IV Prostate Cancer" ], "interventions": [ { "name": "mitoxantrone hydrochloride", "type": "DRUG" }, { "name": "ixabepilone", "type": "DRUG" }, { "name": "prednisone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 100, "start_date": "2006-04", "completion_date": "2010-11", "has_results": true, "last_update_posted_date": "2017-10-31", "last_synced_at": "2026-09-24T06:04:59.218Z", "location_count": 2, "location_summary": "San Francisco, California • Madison, Wisconsin", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Madison", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT00331344" }, { "nct_id": "NCT00003407", "title": "Amifostine & High-Dose Combination Chemotherapy in Treating Patients With Acute ML or CML", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Drug/Agent Toxicity by Tissue/Organ", "Leukemia", "Myelodysplastic Syndromes", "Neutropenia" ], "interventions": [ { "name": "amifostine trihydrate", "type": "DRUG" }, { "name": "cytarabine", "type": "DRUG" }, { "name": "mitoxantrone hydrochloride", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Rush University Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 0, "start_date": "2001-02-13", "completion_date": "2004-04-07", "has_results": false, "last_update_posted_date": "2023-02-02", "last_synced_at": "2026-09-24T06:04:59.218Z", "location_count": 4, "location_summary": "Chicago, Illinois • Kankakee, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Kankakee", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00003407" }, { "nct_id": "NCT01513603", "title": "Trial of Cladribine, Cytarabine, Mitoxantrone, Filgrastim (CLAG-M) in Relapsed Acute Lymphoblastic Leukemia", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Acute Lymphoblastic Leukemia", "Lymphoblastic Lymphoma", "Burkitts Leukemia/Lymphoma", "Chronic Myelogenous Leukemia" ], "interventions": [ { "name": "CLAG-M", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "New York Medical College", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 50, "start_date": "2012-01", "completion_date": "2014-01", "has_results": false, "last_update_posted_date": "2012-01-20", "last_synced_at": "2026-09-24T06:04:59.218Z", "location_count": 1, "location_summary": "Valhalla, New York", "locations": [ { "city": "Valhalla", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01513603" }, { "nct_id": "NCT02400281", "title": "Study of Crenolanib Combined With Chemotherapy in FLT3-mutated Acute Myeloid Leukemia Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Acute Myeloid Leukemia" ], "interventions": [ { "name": "Crenolanib besylate", "type": "DRUG" }, { "name": "Idarubicin", "type": "DRUG" }, { "name": "Cytarabine", "type": "DRUG" }, { "name": "Azacytidine", "type": "DRUG" }, { "name": "Mitoxantrone", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "G-CSF", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Arog Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 28, "start_date": "2015-09", "completion_date": "2020-07-15", "has_results": true, "last_update_posted_date": "2024-07-03", "last_synced_at": "2026-09-24T06:04:59.218Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02400281" }, { "nct_id": "NCT01249430", "title": "Azacitidine in Combination With Mitoxantrone, Etoposide Phosphate, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Recurrent Adult Acute Myeloid Leukemia", "Refractory Acute Myeloid Leukemia" ], "interventions": [ { "name": "Azacitidine", "type": "DRUG" }, { "name": "Cytarabine", "type": "DRUG" }, { "name": "Etoposide Phosphate", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Mitoxantrone Hydrochloride", "type": "DRUG" }, { "name": "Pharmacological Study", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 24, "start_date": "2011-01-20", "completion_date": "2013-05-24", "has_results": false, "last_update_posted_date": "2017-09-21", "last_synced_at": "2026-09-24T06:04:59.218Z", "location_count": 1, "location_summary": "Columbus, Ohio", "locations": [ { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT01249430" }, { "nct_id": "NCT00208975", "title": "Phase II Study of Fludarabine and Mitoxantrone, Followed by GM-CSF(Granulocyte-macrophage Colony-stimulating Factor) and Rituximab", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lymphoma" ], "interventions": [ { "name": "Mitoxantrone/Cyclophosphamide, Fludarabine, Rituximab and GM-CSF", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Emory University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 15, "start_date": "2002-07", "completion_date": "2011-09", "has_results": true, "last_update_posted_date": "2012-06-28", "last_synced_at": "2026-09-24T06:04:59.218Z", "location_count": 1, "location_summary": "Atlanta, Georgia", "locations": [ { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT00208975" }, { "nct_id": "NCT00002565", "title": "Combination Chemotherapy in Treating Patients With Intermediate-Grade or Immunoblastic Non-Hodgkin's Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Lymphoma" ], "interventions": [ { "name": "bleomycin sulfate", "type": "BIOLOGICAL" }, { "name": "CHOP regimen", "type": "DRUG" }, { "name": "cisplatin", "type": "DRUG" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "cytarabine", "type": "DRUG" }, { "name": "doxorubicin hydrochloride", "type": "DRUG" }, { "name": "etoposide", "type": "DRUG" }, { "name": "idarubicin", "type": "DRUG" }, { "name": "ifosfamide", "type": "DRUG" }, { "name": "mesna", "type": "DRUG" }, { "name": "methylprednisolone", "type": "DRUG" }, { "name": "mitoxantrone hydrochloride", "type": "DRUG" }, { "name": "prednisone", "type": "DRUG" }, { "name": "vincristine sulfate", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "15 Years", "maximum_age": null, "sex": "ALL", "summary": "15 Years and older" }, "enrollment_count": 61, "start_date": "1994-05-25", "completion_date": "2007-02-05", "has_results": false, "last_update_posted_date": "2018-11-14", "last_synced_at": "2026-09-24T06:04:59.218Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00002565" }, { "nct_id": "NCT00004071", "title": "Mitoxantrone and Prednisone With or Without Leflunomide in Treating Patients With Stage IV Prostate Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Prostate Cancer" ], "interventions": [ { "name": "leflunomide", "type": "DRUG" }, { "name": "mitoxantrone hydrochloride", "type": "DRUG" }, { "name": "prednisone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": null, "start_date": "1999-08", "completion_date": "2007-09", "has_results": false, "last_update_posted_date": "2012-09-11", "last_synced_at": "2026-09-24T06:04:59.218Z", "location_count": 3, "location_summary": "Boca Raton, Florida • Fort Myers, Florida • New York, New York", "locations": [ { "city": "Boca Raton", "state": "Florida" }, { "city": "Fort Myers", "state": "Florida" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00004071" }, { "nct_id": "NCT00100477", "title": "Use of Topotecan in Patients With Refractory Acute Leukemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non-Hodgkin's Lymphoma", "Leukemia" ], "interventions": [ { "name": "Topotecan", "type": "DRUG" }, { "name": "Mitozantrone", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "US Department of Veterans Affairs", "sponsor_class": "FED", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "18 Years to 60 Years" }, "enrollment_count": 10, "start_date": "1998-08", "completion_date": "2001-06", "has_results": false, "last_update_posted_date": "2013-09-25", "last_synced_at": "2026-09-24T06:04:59.218Z", "location_count": 1, "location_summary": "Gainesville, Florida", "locations": [ { "city": "Gainesville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00100477" }, { "nct_id": "NCT00906945", "title": "Chemosensitization With Plerixafor Plus G-CSF in Acute Myeloid Leukemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Leukemia, Myeloid, Acute" ], "interventions": [ { "name": "G-CSF", "type": "DRUG" }, { "name": "Plerixafor", "type": "DRUG" }, { "name": "Mitoxantrone", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Cytarabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Washington University School of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 39, "start_date": "2011-02", "completion_date": "2015-09", "has_results": true, "last_update_posted_date": "2017-04-04", "last_synced_at": "2026-09-24T06:04:59.218Z", "location_count": 3, "location_summary": "Boston, Massachusetts • St Louis, Missouri • Houston, Texas", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00906945" } ] }